Phase 3 Open-Label Crossover Pharmacodynamic Study to Evaluate the Acid-inhibitory Effect of TAK-438 20 mg With Esomeprazole 20 mg or Rabeprazole Sodium 10 mg in Healthy Adult Male Subjects

Trial Profile

Phase 3 Open-Label Crossover Pharmacodynamic Study to Evaluate the Acid-inhibitory Effect of TAK-438 20 mg With Esomeprazole 20 mg or Rabeprazole Sodium 10 mg in Healthy Adult Male Subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Oct 2016

At a glance

  • Drugs Vonoprazan (Primary) ; Esomeprazole; Rabeprazole
  • Indications Dyspepsia; Gastro-oesophageal reflux; Helicobacter infections; NSAID-induced ulcer; Peptic ulcer; Reflux oesophagitis
  • Focus Pharmacodynamics; Registrational
  • Sponsors Takeda
  • Most Recent Events

    • 12 Jul 2015 Results published in the Alimentary Pharmacology and Therapeutics.
    • 07 May 2014 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top